A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data. An abstract and poster presented at the 2023 American ...
The association between myelodysplastic syndromes (MDS) and inflammatory bowel diseases (IBD): Analysis of Nationwide Inpatient Sample (NIS) database. This is an ASCO Meeting Abstract from the 2021 ...
As such, important advancements have been made toward the dissection of MDS clinical heterogeneity that have incorporated both clinical and molecular characteristics. In this review, we will discuss ...
Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), ...
Risk scoring methods continue to evolve with increased understanding of the factors that affect specific patient group outcomes in MDS. Diagnosis of MDS is currently based on morphology, but can be ...
The Phase 3 portion of the IMerge Phase 2/3 study is a double-blind, 2:1 randomized, placebo-controlled clinical trial to evaluate imetelstat in patients with IPSS Low or Intermediate-1 risk (lower ...
A flow cytometric score developed in 2012, which uses 4 parameters to distinguish low-grade myelodysplastic syndromes (MDS) from nonclonal cytopenias, is simple and practical for screening patients ...
Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found. Allogeneic hematopoietic cell transplantation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results